Suppr超能文献

将电子药物负担指数风险评估工具整合到家庭药物评估中:减少抗胆碱能和镇静药物的使用

Integration of an electronic Drug Burden Index risk assessment tool into Home Medicines Reviews: deprescribing anticholinergic and sedative medications.

作者信息

Kouladjian O'Donnell Lisa, Gnjidic Danijela, Chen Timothy F, Hilmer Sarah N

机构信息

Departments of Clinical Pharmacology and Aged Care, Level 13 Kolling Building, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia.

School of Pharmacy, Faculty of Medicine and Health and Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.

出版信息

Ther Adv Drug Saf. 2019 Mar 5;10:2042098619832471. doi: 10.1177/2042098619832471. eCollection 2019.

Abstract

BACKGROUND

Our aim in this research was to establish whether integrating an electronically generated calculation and report on the Drug Burden Index (DBI) in the Home Medicines Review (HMR) setting is an accurate, feasible and useful risk assessment tool to assess risk of anticholinergic and sedative medications; and to establish whether the intervention of DBI together with HMR is associated with a reduced use of anticholinergic and sedative medications in older community-dwelling adults in Australia.

METHODS

An interventional feasibility study was conducted. Accredited clinical pharmacists (APs) were recruited to participate. Each AP was educated on implementation of the DBI into HMR practice and given access to the DBI Calculator© web-based software to generate the DBI report for inclusion in HMR reports for general practitioners (GPs). APs recruited patients (⩾65 years) who were referred to them for HMRs. Patients were sent a letter about their DBI exposure, and a prompt to visit their GP to discuss their medication management options. GPs, APs and patients were asked to evaluate the feasibility and utility of the DBI report. A medication inventory was collected from patients at the time of the HMR and at 3 months to determine whether the intervention affected deprescribing of medications with anticholinergic and sedative effects.

RESULTS

Regarding the feasibility of the DBI report as a risk assessment tool within HMR, 89% of APs and 67% of GPs agreed that it would be feasible. The DBI Calculator© was potentially inaccurate, as 26% of DBI scores were underestimated and 7% were overestimated (at baseline). At 3 months, the median (interquartile range) DBI for patients ( = 100) significantly decreased from 0.82 (0-1.33) to 0.67 (0-1.29) ( = 0.014). Additionally, of patients with a DBI > 0 ( = 66), 36.4% had their DBI score decrease, and 6.1% had a score increase.

CONCLUSION

This study demonstrated that integration of the DBI Calculator© into HMR is a feasible and useful method to prompt deprescribing of anticholinergic and sedative medications in older adults. There is potential for the accuracy of the web-based platform to be improved.

REGISTRATION OF TRIAL

Name: Feasibility study of the Drug Burden Index with Home Medicines Review.Website: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368523Trial ID: ACTRN 12615000539538.

摘要

背景

本研究的目的是确定在家庭药物审查(HMR)环境中纳入电子生成的药物负担指数(DBI)计算和报告是否是一种准确、可行且有用的风险评估工具,以评估抗胆碱能和镇静药物的风险;并确定DBI与HMR相结合的干预措施是否与澳大利亚社区居住的老年人减少使用抗胆碱能和镇静药物有关。

方法

进行了一项干预性可行性研究。招募了经认可的临床药剂师(AP)参与。每位AP都接受了关于将DBI应用于HMR实践的培训,并有权使用DBI计算器©基于网络的软件来生成DBI报告,以便纳入全科医生(GP)的HMR报告中。AP招募了被转介进行HMR的患者(年龄≥65岁)。向患者发送了一封关于其DBI暴露情况的信,并提示他们拜访其GP以讨论药物管理方案。要求GP、AP和患者评估DBI报告的可行性和实用性。在HMR时和3个月时收集患者的药物清单,以确定干预措施是否影响了停用具有抗胆碱能和镇静作用的药物。

结果

关于DBI报告作为HMR内风险评估工具的可行性,89%的AP和67%的GP认为是可行的。DBI计算器©可能不准确,因为26%的DBI分数被低估,7%被高估(在基线时)。在3个月时,患者(n = 100)的DBI中位数(四分位间距)从0.82(0 - 1.33)显著降至0.67(0 - 1.29)(P = 0.014)。此外,DBI > 0的患者(n = 66)中,36.4%的DBI分数下降,6.1%分数上升。

结论

本研究表明,将DBI计算器©纳入HMR是一种可行且有用的方法,可促使老年人停用抗胆碱能和镇静药物。基于网络的平台在准确性方面有改进的潜力。

试验注册

名称:家庭药物审查中药物负担指数的可行性研究。网站:https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id = 368523试验编号:ACTRN 12615000539538

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5635/6402056/ce9762fc742a/10.1177_2042098619832471-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验